$SVRA
Savara Inc

2019 Q1 Form 10-K Financial Statement

#000156459019007585 Filed on March 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 2017 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.760M $10.65M $2.670M
YoY Change 55.93% 19.93% 38.34%
% of Gross Profit
Research & Development $1.400M $37.17M $6.440M
YoY Change -83.61% 100.8% 7950.0%
% of Gross Profit
Depreciation & Amortization $307.0K $526.0K $90.00K
YoY Change 186.92% 44.9% -156.25%
% of Gross Profit
Operating Expenses $1.400M $37.17M $9.200M
YoY Change -86.56% 24.09% 353.2%
Operating Profit -$12.92M -$9.296M
YoY Change -59.76% 129.87%
Interest Expense -$20.00K $11.00K -$120.0K
YoY Change -80.77% -99.05% -14.29%
% of Operating Profit
Other Income/Expense, Net $960.0K $1.450M
YoY Change -534.39% -141.73%
Pretax Income -$12.11M -$70.03M -$9.310M
YoY Change -61.43% 109.47% 10.31%
Income Tax $0.00 -$7.057M -$10.00K
% Of Pretax Income
Net Earnings -$12.11M -$61.52M -$6.502M
YoY Change -54.89% 106.45% 63.82%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$336.2K -$1.847M -$225.9K
COMMON SHARES
Basic Shares Outstanding 35.34M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $105.2M $110.8M $94.30M
YoY Change 23.76% 17.5% 603.73%
Cash & Equivalents $25.67M $24.30M $22.12M
Short-Term Investments $79.50M $86.50M $72.20M
Other Short-Term Assets $800.0K $800.0K $2.500M
YoY Change -50.0% -68.0% 212.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $107.5M $113.3M $97.86M
YoY Change 22.72% 15.73% 570.3%
LONG-TERM ASSETS
Property, Plant & Equipment $1.700M $500.0K $925.0K
YoY Change 112.5% -44.44% 15.63%
Goodwill $26.80M $27.08M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.100M $100.0K $131.0K
YoY Change 0.0% 0.0%
Total Long-Term Assets $40.80M $39.00M $61.76M
YoY Change -1.21% -36.79% 331.92%
TOTAL ASSETS
Total Short-Term Assets $107.5M $113.3M $97.86M
Total Long-Term Assets $40.80M $39.00M $61.76M
Total Assets $148.3M $152.3M $159.6M
YoY Change 15.05% -4.57% 452.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.500M $3.900M $2.784M
YoY Change 2.94% 39.29% 456.8%
Accrued Expenses $5.100M $3.100M $2.966M
YoY Change 168.42% 3.33% 18.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $300.0K
YoY Change -100.0% -25.0%
Total Short-Term Liabilities $8.900M $7.300M $6.000M
YoY Change 64.81% 21.67% 23.3%
LONG-TERM LIABILITIES
Long-Term Debt $24.70M $24.50M $15.10M
YoY Change 62.5% 62.25% 277.5%
Other Long-Term Liabilities $12.90M $12.30M $12.10M
YoY Change 8.4% 1.65% 8.04%
Total Long-Term Liabilities $37.60M $36.80M $27.20M
YoY Change 38.75% 35.29% 78.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.900M $7.300M $6.000M
Total Long-Term Liabilities $37.60M $36.80M $27.20M
Total Liabilities $46.50M $44.10M $40.32M
YoY Change 32.1% 9.43% 92.47%
SHAREHOLDERS EQUITY
Retained Earnings -$68.20M
YoY Change 77.58%
Common Stock $186.6M
YoY Change 5875.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $101.8M $108.2M $119.3M
YoY Change
Total Liabilities & Shareholders Equity $148.3M $152.3M $159.6M
YoY Change 15.05% -4.57% 451.7%

Cashflow Statement

Concept 2019 Q1 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$12.11M -$61.52M -$6.502M
YoY Change -54.89% 106.45% 63.82%
Depreciation, Depletion And Amortization $307.0K $526.0K $90.00K
YoY Change 186.92% 44.9% -156.25%
Cash From Operating Activities -$10.86M -$39.28M -$9.470M
YoY Change 12.28% 39.11% -69.54%
INVESTING ACTIVITIES
Capital Expenditures $96.00K $141.0K -$440.0K
YoY Change 405.26% -71.52%
Acquisitions
YoY Change
Other Investing Activities $7.420M -$13.48M -$38.62M
YoY Change -21.15% -80.36% -353.91%
Cash From Investing Activities $7.320M -$13.62M -$39.06M
YoY Change -22.04% -80.3% -356.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.890M $505.0K
YoY Change 891.89% -69.69%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.896M 55.19M 50.76M
YoY Change 1706.64% -47.97% 1898.43%
NET CHANGE
Cash From Operating Activities -10.86M -39.28M -9.470M
Cash From Investing Activities 7.320M -13.62M -39.06M
Cash From Financing Activities 4.896M 55.19M 50.76M
Net Change In Cash 1.370M 2.180M 2.230M
YoY Change 136900.0% -75.08% -116.72%
FREE CASH FLOW
Cash From Operating Activities -$10.86M -$39.28M -$9.470M
Capital Expenditures $96.00K $141.0K -$440.0K
Free Cash Flow -$10.96M -$39.42M -$9.030M
YoY Change 13.05% 37.2% -70.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Trading Symbol
TradingSymbol
SVRA
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35336438
CY2018Q2 dei Entity Public Float
EntityPublicFloat
146673125
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24301000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22121000
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
86529000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
72192000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2514000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3551000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
113344000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
97864000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
522000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
925000
CY2018Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
11372000
CY2017Q4 svra In Process Research And Development
InProcessResearchAndDevelopment
33626000
CY2018Q4 us-gaap Goodwill
Goodwill
26918000
CY2017Q4 us-gaap Goodwill
Goodwill
27082000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
131000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
131000
CY2018Q4 us-gaap Assets
Assets
152287000
CY2017Q4 us-gaap Assets
Assets
159628000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3879000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2784000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3334000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2966000
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
41000
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
265000
CY2018Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
24530000
CY2017Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
14775000
CY2018Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
12214000
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
11948000
CY2018Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
70000
CY2018Q4 us-gaap Liabilities
Liabilities
44068000
CY2018 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
21692000
CY2018 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
11000
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1161000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
71000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-218000
CY2017 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1816000
CY2018 svra Change In Fair Value Of Financial Instruments Net Of Contingent Consideration
ChangeInFairValueOfFinancialInstrumentsNetOfContingentConsideration
-64000
CY2017 svra Change In Fair Value Of Financial Instruments Net Of Contingent Consideration
ChangeInFairValueOfFinancialInstrumentsNetOfContingentConsideration
-280000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-70027000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33431000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8511000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3634000
CY2017 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
578000
CY2017 svra Deemed Dividend On Beneficial Conversion Feature
DeemedDividendOnBeneficialConversionFeature
404000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-61516000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30779000
CY2016Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
43861000
CY2017 svra Temporary Equity Value Conversion Of Stock
TemporaryEquityValueConversionOfStock
-44439000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-35875000
CY2017 svra Accretion Of Redeemable Convertible Preferred Stock Deficit
AccretionOfRedeemableConvertiblePreferredStockDeficit
-578000
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
10045000
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
44438000
CY2017 svra Adjustments To Additional Paid In Capital Reclassification Of Warrant Liability
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability
370000
CY2017 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
404000
CY2017 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
35846000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
89598000
CY2017 svra Issuance Of Common Stock Upon At The Market Offering Net
IssuanceOfCommonStockUponAtTheMarketOfferingNet
1665000
CY2017 svra Adjustments To Additional Paid In Capital Issuance Of Call Option Derivative
AdjustmentsToAdditionalPaidInCapitalIssuanceOfCallOptionDerivative
344000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
45792000
CY2018 svra Issuance Of Common Stock Upon At The Market Offering Net
IssuanceOfCommonStockUponAtTheMarketOfferingNet
505000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58000
CY2018 svra Issuance Of Common Stock Upon Exercise Of Warrants Amount
IssuanceOfCommonStockUponExerciseOfWarrantsAmount
19000
CY2018 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
995000
CY2018 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
78000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3737000
CY2018 us-gaap Profit Loss
ProfitLoss
-61516000
CY2017 us-gaap Profit Loss
ProfitLoss
-29797000
CY2018 svra Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
-64000
CY2017 svra Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
-280000
CY2018 svra Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
266000
CY2017 svra Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
2240000
CY2018 us-gaap Paid In Kind Interest
PaidInKindInterest
75000
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
336000
CY2018 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
995000
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
468000
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
401000
CY2018 svra Accretion On Discount To Short Term Investments And Convertible Promissory Notes
AccretionOnDiscountToShortTermInvestmentsAndConvertiblePromissoryNotes
900000
CY2017 svra Accretion On Discount To Short Term Investments And Convertible Promissory Notes
AccretionOnDiscountToShortTermInvestmentsAndConvertiblePromissoryNotes
136000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
3737000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
552000
CY2017 svra Issuance Of Call Option Derivative
IssuanceOfCallOptionDerivative
344000
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-7057000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2820000
CY2017 svra Increase Decrease In Grant And Award Receivable
IncreaseDecreaseInGrantAndAwardReceivable
-400000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-900000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2564000
CY2018 svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
1546000
CY2017 svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
133000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39275000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28234000
CY2017 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3442000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
141000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
495000
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
122494000
CY2017 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
76862000
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
98746000
CY2017 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
4800000
CY2018 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
10270000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13619000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-69115000
CY2018 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
9365000
CY2017 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
11327000
CY2018 svra Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants
ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants
19000
CY2017 svra Proceeds From Issuance Of Common Stock Upon Exercise Of Warrants
ProceedsFromIssuanceOfCommonStockUponExerciseOfWarrants
384000
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
45792000
CY2017 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
89598000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
505000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1666000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
58000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3569000
CY2018 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
546000
CY2017 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
460000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55193000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
106089000
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-119000
CY2017 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2180000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8748000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22121000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13373000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24301000
CY2017 svra Non Cash Extinguishment And Derecognition Of Put Options
NonCashExtinguishmentAndDerecognitionOfPutOptions
2202000
CY2017 svra Shares Issued In Connection Of Business Combination And Assumed Equity Awards
SharesIssuedInConnectionOfBusinessCombinationAndAssumedEquityAwards
35846000
CY2017 svra Non Cash Accretion Of Redeemable Convertible Preferred Stock
NonCashAccretionOfRedeemableConvertiblePreferredStock
578000
CY2017 svra Non Cash Beneficial Conversion Feature
NonCashBeneficialConversionFeature
404000
CY2018 svra Common Stock Issued For In Process Research And Development Net
CommonStockIssuedForInProcessResearchAndDevelopmentNet
995000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
1406000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
733000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Use of Estimates </font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management&#8217;s estimates include those related to the accrual of research and development costs, the valuation of preferred and common shares, certain financial instruments recorded at fair value, stock-based compensation, contingent consideration, and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Accordingly, actual results could be materially different from those estimates. </font></p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Concentration of Credit Risk </font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and foreign exchange derivatives not designated as hedging. The Company places its cash and cash equivalents with a limited number of financial institutions and at times may exceed the amount of insurance provided on such deposits. </font></p>
CY2018Q4 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2044000
CY2018Q4 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
371000
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018 svra Liquid Investments Maturity Period
LiquidInvestmentsMaturityPeriod
three months or less
CY2018 svra Percentage Of Present Value Of Minimum Lease Payments Exceeding Fair Value Of Equipment Determined Lease As Capital Lease
PercentageOfPresentValueOfMinimumLeasePaymentsExceedingFairValueOfEquipmentDeterminedLeaseAsCapitalLease
0.90
CY2018 svra Date Of Agreement
DateOfAgreement
2018-10-08
CY2018 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
11812000
CY2018Q4 svra Contingent Milestones Or Co Development Commitments Incurred
ContingentMilestonesOrCoDevelopmentCommitmentsIncurred
0
CY2018Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
1263000
CY2017Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
834000
CY2018Q4 svra Prepaid Clinical Trial Costs
PrepaidClinicalTrialCosts
561000
CY2017Q4 svra Prepaid Clinical Trial Costs
PrepaidClinicalTrialCosts
2129000
CY2018Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
421000
CY2017Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
196000
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
162000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
158000
CY2017Q4 svra Forward Currency Exchange Derivative Current
ForwardCurrencyExchangeDerivativeCurrent
40000
CY2018Q4 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
107000
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
30000
CY2018Q4 svra Accrued Compensation
AccruedCompensation
643000
CY2018Q4 svra Forward Currency Exchange Derivative
ForwardCurrencyExchangeDerivative
26000
CY2018Q4 us-gaap Deferred Revenue
DeferredRevenue
250000
CY2018Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
86559000
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
72238000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
46000
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
86529000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
72192000
CY2018 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1890000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1776000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1368000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
851000
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
400000
CY2018Q4 svra Principal Payments Of Debt And End Of Term Charge Non Current
PrincipalPaymentsOfDebtAndEndOfTermChargeNonCurrent
25033000
CY2018Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
268000
CY2018Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
235000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2000000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
12000000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
12500000
CY2018Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
26500000
CY2018Q4 svra Unamortized End Of Term Charge
UnamortizedEndOfTermCharge
1467000
CY2018Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
503000
CY2018Q4 us-gaap Line Of Credit
LineOfCredit
24530000
CY2018Q4 svra Common Stock And Preferred Stock Shares Authorized
CommonStockAndPreferredStockSharesAuthorized
201000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4910016
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4072391
CY2016Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
11927875
CY2016Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
11927875
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1676502
CY2017Q1 svra Operating Lease Office Space
OperatingLeaseOfficeSpace
13707
CY2017Q1 svra Lease Commencement Date
LeaseCommencementDate
2017-07-01
CY2018 svra Lease Commencement Date
LeaseCommencementDate
2018-11-01
CY2017Q4 svra Lease Commencement Date
LeaseCommencementDate
2018-01-01
CY2017Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-05-31
CY2018 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-09-30
CY2017Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-07-31
CY2017Q1 svra Lease Agreement Date
LeaseAgreementDate
2014-06-19
CY2018 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
100000
CY2017Q4 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
200000
CY2018 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
500000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
843000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
471000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
175000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
60000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1549000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
45000
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
45000
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
4000
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
41000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2018 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-1330000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1487000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
4399000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
3427000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
1164000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
1691000
CY2018 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
56000
CY2017 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
762000
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-814000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-1330000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-814000
CY2018 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-2626000
CY2018 svra Deferred Federal Foreign Income Tax Expense Benefit
DeferredFederalForeignIncomeTaxExpenseBenefit
-7181000
CY2017 svra Deferred Federal Foreign Income Tax Expense Benefit
DeferredFederalForeignIncomeTaxExpenseBenefit
-2820000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-14706000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-11367000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8692000
CY2018 svra Employment Agreement Description
EmploymentAgreementDescription
Upon termination without cause, and not as a result of death or disability, or resignation for good reason, each of such officers is entitled to receive a payment of base salary for twelve months and a pro-rated portion of their unpaid bonus following termination of employment, and such officer will be entitled to continue to receive coverage under medical and dental benefit plans for twelve months or until such officer is covered under a separate plan from another employer. Upon a termination other than for cause or resignation for good reason within twelve months following a change in control, each of such officers is entitled to receive a payment of base salary for eighteen months and one-hundred percent of their unpaid bonus following termination of employment and such officer will be entitled to continue to receive coverage under medical and dental benefit plans for twelve months or until such officer is covered under a separate plan from another employer and will also be entitled to certain acceleration of such officer’s outstanding nonvested options at the time of such termination.
CY2018 svra Percentage Of Unpaid Bonus To Be Paid Upon Termination
PercentageOfUnpaidBonusToBePaidUponTermination
1.00
CY2018 svra Purchase Price Of Common Stock Covered By Stock Option As Percentage Of Fair Market Value Of Common Stock
PurchasePriceOfCommonStockCoveredByStockOptionAsPercentageOfFairMarketValueOfCommonStock
Less than 100%
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.00
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3077264
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1292671
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3737000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
552000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-48868000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21942000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-21159000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-11489000
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-4555000
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2820000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-305000
CY2017 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1363000
CY2017 svra Income Tax Reconciliation Note Conversion
IncomeTaxReconciliationNoteConversion
618000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
4096000
CY2017 svra Income Tax Reconciliation Transaction Costs
IncomeTaxReconciliationTransactionCosts
657000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
987000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
486000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8700000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7900000
CY2018Q4 svra Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
14000
CY2017Q4 svra Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
87000
CY2017Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
378000
CY2018Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2845000
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
7181000
CY2018Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
237000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3096000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2018Q1 svra Increase Decrease Earnings Per Share Basic And Diluted
IncreaseDecreaseEarningsPerShareBasicAndDiluted
-0.02
CY2018Q2 svra Increase Decrease Earnings Per Share Basic And Diluted
IncreaseDecreaseEarningsPerShareBasicAndDiluted
-0.01
CY2018Q3 svra Increase Decrease Earnings Per Share Basic And Diluted
IncreaseDecreaseEarningsPerShareBasicAndDiluted
-0.01
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
7646000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21406000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13194000
CY2018Q4 svra Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
208000
CY2017Q4 svra Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
6000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
12706000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
9770000
CY2018Q4 svra Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
318000
CY2017Q4 svra Deferred Tax Assets Accrued Liabilities And Other
DeferredTaxAssetsAccruedLiabilitiesAndOther
345000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
34638000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23315000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
31542000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
15669000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31542000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22850000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
7181000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 svra Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
-2800000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
23100000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
9500000
CY2018Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1800000
CY2018Q4 svra Percentage Increase In Shareholders Ownership Interest
PercentageIncreaseInShareholdersOwnershipInterest
0.05
CY2018Q4 svra Minimum Percentage Points Change In Ownership Interest
MinimumPercentagePointsChangeInOwnershipInterest
0.0050
CY2018 svra Change In Ownership Interest Period
ChangeInOwnershipInterestPeriod
P3Y
CY2018Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2018 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2017 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4135016
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4088581
CY2018 svra Undistributed Earnings And Net Income Loss Attributable To Common Stockholders Basic And Diluted
UndistributedEarningsAndNetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-61516000
CY2017 svra Undistributed Earnings And Net Income Loss Attributable To Common Stockholders Basic And Diluted
UndistributedEarningsAndNetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-30779000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32107000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11906000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12784000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-13248000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-26849000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-11593000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-12560000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-10514000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.86
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4774000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9343000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6543000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-9296000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-4974000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-11504000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-6817000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-6502000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.97
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.90

Files In Submission

Name View Source Status
0001564590-19-007585-index-headers.html Edgar Link pending
0001564590-19-007585-index.html Edgar Link pending
0001564590-19-007585.txt Edgar Link pending
0001564590-19-007585-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2cixwwrn4nt000001.jpg Edgar Link pending
g2cixwwrn4nt000002.jpg Edgar Link pending
gbfceialz4xw000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
svra-10k_20181231.htm Edgar Link pending
svra-20181231.xml Edgar Link completed
svra-20181231.xsd Edgar Link pending
svra-20181231_cal.xml Edgar Link unprocessable
svra-20181231_def.xml Edgar Link unprocessable
svra-20181231_lab.xml Edgar Link unprocessable
svra-20181231_pre.xml Edgar Link unprocessable
svra-ex1031_244.htm Edgar Link pending
svra-ex231_241.htm Edgar Link pending
svra-ex311_8.htm Edgar Link pending
svra-ex312_10.htm Edgar Link pending
svra-ex321_9.htm Edgar Link pending
svra-ex419_591.htm Edgar Link pending
svra-ex420_592.htm Edgar Link pending